GYRE CEO Luo Ying files Form 3 holdings
GYRE THERAPEUTICS, INC. chief executive officer Luo Ying filed a Form 3 that lists existing equity holdings in the company.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
3
Rhea-AI Filing Summary
GYRE THERAPEUTICS, INC. chief executive officer Luo Ying filed a Form 3 that lists existing equity holdings in the company. The filing shows indirect ownership through a spouse of 2,575,541 shares of common stock, plus multiple stock option awards held both directly and indirectly with exercise prices between $0.32 and $5.98 and expirations from 2028 through 2034.
Insider Trade Summary
8 transactions reported
Mixed
8 txns
Insider
Luo Ying
Role
Chief Executive Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 5,515,236 contracts (Direct);
Stock Option (Right to Buy) — 2,262,755 contracts (Indirect, By Spouse);
Common Stock — 2,575,541 shares (Indirect, By Spouse)
Footnotes (2)
- F1. These options are vested in full.
- F2. This option represents a right to purchase 235,273 shares of the Issuer's common stock, one quarter of which vested on November 13, 2025, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
Key Figures
Indirect common shares: 2,575,541 shares
Indirect option at $0.75: 2,262,755 shares
Direct option at $5.98: 235,273 shares
+5 more
8 metrics
Indirect common shares
2,575,541 shares
Common Stock held indirectly By Spouse following transaction
Indirect option at $0.75
2,262,755 shares
Underlying Common Stock, exercise price $0.7500, expires 2030-10-31
Direct option at $5.98
235,273 shares
Underlying Common Stock, exercise price $5.9800, expires 2034-11-12
Direct option at $2.00 (2031)
988,624 shares
Underlying Common Stock, exercise price $2.0000, expires 2031-04-16
Direct option at $2.00 (2030)
199,626 shares
Underlying Common Stock, exercise price $2.0000, expires 2030-12-17
Direct option at $0.75
3,378,763 shares
Underlying Common Stock, exercise price $0.7500, expires 2030-10-31
Direct option at $0.93
237,650 shares
Underlying Common Stock, exercise price $0.9300, expires 2030-01-12
Direct option at $0.32
475,300 shares
Underlying Common Stock, exercise price $0.3200, expires 2028-06-07
Key Terms
Form 3, Stock Option (Right to Buy), indirect ownership, exercise price, +1 more
5 terms
Form 3 regulatory
"INSIDER FILING DATA (Form 3)"
Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.
Stock Option (Right to Buy) financial
"security_title": "Stock Option (Right to Buy)""
indirect ownership financial
""ownership_type": "indirect", "nature_of_ownership": "By Spouse""
exercise price financial
""conversion_or_exercise_price": "0.7500""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"with the remaining three quarters vesting in equal monthly installments"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does Luo Ying’s Form 3 filing for GYRE THERAPEUTICS (GYRE) show?
The Form 3 lists Luo Ying’s existing equity interests in GYRE THERAPEUTICS, INC., including indirect common stock held through a spouse and several stock option grants with defined exercise prices and expiration dates, rather than reporting any new stock purchases or sales.
What stock options linked to GYRE common stock are indirectly held in Luo Ying’s Form 3?
One stock option position is listed as indirectly owned "By Spouse" with an exercise price of $0.75 per share, covering 2,262,755 underlying shares of GYRE common stock and expiring on October 31, 2030, reflecting an existing derivative holding rather than a new option exercise.
What direct stock option holdings does Luo Ying report in the GYRE Form 3?
Directly held options include grants over 235,273, 988,624, 199,626, 3,378,763, 237,650, and 475,300 underlying common shares, with exercise prices between $0.32 and $5.98 and expirations from 2028 through 2034, illustrating several long-dated incentive awards tied to GYRE stock.
Does Luo Ying’s GYRE Form 3 describe vesting terms for any stock options?
A footnote explains that one option over 235,273 shares vests one quarter on November 13, 2025, with the remaining three quarters vesting in equal monthly installments over three years, contingent on continued service, highlighting time-based vesting conditions on part of the equity compensation.
Are any of the options in Luo Ying’s GYRE Form 3 already vested?
A footnote states that certain options "are vested in full," indicating that some grants have fully satisfied their vesting requirements. Fully vested options can typically be exercised subject to their terms, while other grants in the filing still vest over a multi-year schedule.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates